IL-6 Plasma Levels Correlate With Cerebral Perfusion Deficits and Infarct Sizes in Stroke Patients Without Associated Infections

Benjamin Hotter, Sarah Hoffmann, Lena Ulm, Christian Meisel, Jochen B Fiebach, Andreas Meisel, Benjamin Hotter, Sarah Hoffmann, Lena Ulm, Christian Meisel, Jochen B Fiebach, Andreas Meisel

Abstract

Introduction: We aimed to investigate several blood-based biomarkers related to inflammation, immunity, and stress response in a cohort of patients without stroke-associated infections regarding their predictive abilities for functional outcome and explore whether they correlate with MRI markers, such as infarct size or location. Methods: We combined the clinical and radiological data of patients participating in two observational acute stroke cohorts: the PREDICT and 1000Plus studies. The following blood-based biomarkers were measured in these patients: monocytic HLA-DR, IL-6, IL-8, IL-10, LBP, MRproANP, MRproADM, CTproET, Copeptin, and PCT. Multiparametric stroke MRI was performed including T2*, DWI, FLAIR, TOF-MRA, and perfusion imaging. Standard descriptive sum statistics were used to describe the sample. Associations were analyzed using Fischer's exact test, independent samples t-test and Spearmans correlation, where appropriate. Results: Demographics and stroke characteristics were as follows: 94 patients without infections, mean age 68 years (SD 10.5), 32.2% of subjects were female, median NIHSS score at admission 3 (IQR 2-5), median mRS 3 months after stroke 1 (IQR 0-2), mean volume of DWI lesion at admission 5.7 ml (SD 12.8), mean FLAIR final infarct volume 10 ml (SD 14.9), cortical affection in 61% of infarctions. Acute DWI lesion volume on admission MRI was moderately correlated to admission/maximum IL-6 as well as maximum LBP. Extent of perfusion deficit and mismatch were moderately correlated to admission/maximum IL-6 levels. Final lesion volume on FLAIR was moderately correlated to admission IL-6 levels. Conclusion: We found IL-6 to be associated with several parameters from acute stroke MRI (acute DWI lesion, perfusion deficit, final infarct size, and affection of cortex) in a cohort of patients not influenced by infections. Clinical Trial Registration: www.ClinicalTrials.gov, identifiers NCT01079728 and NCT00715533.

Keywords: IL-6; MRI; biomarker; neuroinflammation; stroke.

Figures

Figure 1
Figure 1
Timeline of the two studies supporting this analysis (A) and study flow chart (B).

References

    1. Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. (2010) 9:105–18. 10.1016/S1474-4422(09)70266-2
    1. Weimar C, Roth MP, Zillessen G, Glahn J, Wimmer MLJ, Busse O, et al. . Complications following acute ischemic stroke. Eur Neurol. (2002) 48:133–40. 10.1159/000065512
    1. Heuschmann PU, Wiedmann S, Wellwood I, Rudd A, Di Carlo A, Bejot Y, et al. . Three-month stroke outcome: the European Registers of Stroke (EROS) investigators. Neurology (2011) 76:159–65. 10.1212/WNL.0b013e318206ca1e
    1. Ntaios G, Faouzi M, Ferrari J, Lang W, Vemmos K, Michel P. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology (2012) 78:1916–22. 10.1212/WNL.0b013e318259e221
    1. Byblow WD, Stinear CM. It is difficult to make predictions, especially about the future. Stroke (2017) 48:3187–8. 10.1161/STROKEAHA.117.019071
    1. Scrutinio D, Lanzillo B, Guida P, Mastropasqua F, Monitillo V, Pusineri M, et al. . Development and validation of a predictive model for functional outcome after stroke rehabilitation: the maugeri model. Stroke (2017) 48:3308–15. 10.1161/STROKEAHA.117.018058
    1. Stinear CM. Prediction of motor recovery after stroke: advances in biomarkers. Lancet Neurol. (2017) 16:826–36. 10.1016/S1474-4422(17)30283-1
    1. Bustamante A, Sobrino T, Giralt D, García-Berrocoso T, Llombart V, Ugarriza I, et al. . Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and meta-analysis. J Neuroimmunol. (2014) 274:215–24. 10.1016/j.jneuroim.2014.07.01
    1. Hoffmann S, Harms H, Ulm L, Nabavi DG, Mackert B-M, Schmehl I, et al. . Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia - The PREDICT study. J Cereb Blood Flow Metab. (2016) 37:3671–82. 10.1177/0271678X16671964
    1. Hotter B, Pittl S, Ebinger M, Oepen G, Jegzentis K, Kudo K, et al. . Prospective study on the mismatch concept in acute stroke patients within the first 24 h after symptom onset - 1000Plus study. BMC Neurol. (2009) 9:60. 10.1186/1471-2377-9-60
    1. Van Wagoner NJ, Benveniste EN. Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol. (1999) 100:124–39. 10.1016/S0165-5728(99)00187-3
    1. Müller B. Cytokine imbalance in non-immunological chronic disease. Cytokine (2002) 18:334–9. 10.1006/cyto.2002.0882
    1. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, et al. . Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke (1995) 26:1393–8. 10.1161/01.STR.26.8.1393
    1. Ormstad H, Aass HCD, Lund-Sørensen N, Amthor K-F, Sandvik L. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. J Neurol. (2011) 258:677–85. 10.1007/s00415-011-6006-0
    1. Waje-Andreassen U, Krakenes J, Ulvestad E, Thomassen L, Myhr KM, Aarseth J, et al. . IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand. (2005) 111:360–5. 10.1111/j.1600-0404.2005.00416.x
    1. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology (2012) 78:720–7. 10.1212/WNL.0b013e318248e50f
    1. Miwa K, Tanaka M, Okazaki S, Furukado S, Sakaguchi M, Kitagawa K. Relations of blood inflammatory marker levels with cerebral microbleeds. Stroke (2011) 42:3202–6. 10.1161/STROKEAHA.111.621193
    1. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, Hori M. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke (2005) 36:768–72. 10.1161/01.STR.0000158915.28329.51
    1. Montaner J, Rovira A, Molina CA, Arenillas JF, Ribó M, Chacón P, et al. . Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab. (2003) 23:1403–7. 10.1097/01.WCB.0000100044.07481.97
    1. Rodríguez-Yánez M, Sobrino T, Arias S, Vázquez-Herrero F, Brea D, Blanco M, et al. . Early biomarkers of clinical-diffusion mismatch in acute ischemic stroke. Stroke (2011) 42:2813–8. 10.1161/STROKEAHA.111.614503
    1. Rodríguez-Yánez M, Castellanos M, Sobrino T, Brea D, Ramos-Cabrer P, Pedraza S, et al. . Interleukin-10 facilitates the selection of patients for systemic thrombolysis. BMC Neurol. (2013) 13:62. 10.1186/1471-2377-13-62
    1. Chamorro A, Amaro S, Vargas M, Obach V, Cervera A, Torres F, et al. . Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J Neurol Neurosurg Psychiatr. (2006) 77:1279–81. 10.1136/jnnp.2006.100800
    1. Klehmet J, Harms H, Richter M, Prass K, Volk HD, Dirnagl U, et al. . Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience (2009) 158:1184–93. 10.1016/j.neuroscience.2008.07.044
    1. Urra X, Cervera Á, Obach V, Climent N, Planas AM, Chamorro A. Monocytes are major players in the prognosis and risk of infection after acute stroke. Stroke (2009) 40:1262–8. 10.1161/STROKEAHA.108.532085
    1. Hug A, Dalpke A, Wieczorek N, Giese T, Lorenz A, Auffarth G, et al. . Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke (2009) 40:3226–32. 10.1161/STROKEAHA.109.557967
    1. Bhandari SS, Davies JE, Struck J, Ng LL. Plasma C-terminal proEndothelin-1 (CTproET-1) is affected by age, renal function, left atrial size and diastolic blood pressure in healthy subjects. Peptides (2014) 52:53–7. 10.1016/j.peptides.2013.12.001
    1. Worthmann H, Tryc AB, Dirks M, Schuppner R, Brand K, Klawonn F, et al. . Lipopolysaccharide binding protein, interleukin-10, interleukin-6 and C-reactive protein blood levels in acute ischemic stroke patients with post-stroke infection. J Neuroinflammation (2015) 12:13. 10.1186/s12974-014-0231-2
    1. Klimiec E, Pera J, Chrzanowska-Wasko J, Golenia A, Slowik A, Dziedzic T. Plasma endotoxin activity rises during ischemic stroke and is associated with worse short-term outcome. J Neuroimmunol. (2016) 297:76–80. 10.1016/j.jneuroim.2016.05.006
    1. Katan M, Moon YP, Paik MC, Mueller B, Huber A, Sacco RL, et al. . Procalcitonin and midregional proatrial natriuretic peptide as markers of ischemic stroke: the Northern Manhattan study. Stroke (2016) 47:1714–9. 10.1161/STROKEAHA.115.011392
    1. Bustamante A, García-Berrocoso T, Penalba A, Giralt D, Simats A, Muchada M, et al. . Sepsis biomarkers reprofiling to predict stroke-associated infections. J Neuroimmunol. (2017) 312:19–23. 10.1016/j.jneuroim.2017.08.012
    1. Seifert-Held T, Pekar T, Gattringer T, Simmet NE, Scharnagl H, Bocksrucker C, et al. . Plasma midregional pro-adrenomedullin improves prediction of functional outcome in ischemic stroke. PLoS ONE (2013) 8:e68768. 10.1371/journal.pone.0068768
    1. Kuriyama N, Ihara M, Mizuno T, Ozaki E, Matsui D, Watanabe I, et al. . Association between mid-regional proadrenomedullin levels and progression of deep white matter lesions in the brain accompanying cognitive decline. J Alzheimers Dis. (2017) 56:1253–62. 10.3233/JAD-160901
    1. Xu Q, Tian Y, Peng H, Li H. Copeptin as a biomarker for prediction of prognosis of acute ischemic stroke and transient ischemic attack: a meta-analysis. Hypertens Res. (2017) 40:465–71. 10.1038/hr.2016.165
    1. Tu W-J, Ma G-Z, Ni Y, Hu X-S, Luo D-Z, Zeng X-W, et al. . Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke. Neurology (2017) 88:1899–905. 10.1212/WNL.0000000000003937
    1. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, et al. . Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. (2009) 66:799–808. 10.1002/ana.21783
    1. Fluri F, Morgenthaler NG, Mueller B, Christ-Crain M, Katan M. Copeptin, procalcitonin and routine inflammatory markers-predictors of infection after stroke. PLoS ONE (2012) 7:e48309. 10.1371/journal.pone.0048309
    1. De Marchis GM, Weck A, Audebert H, Benik S, Foerch C, Buhl D, et al. . Copeptin for the prediction of recurrent cerebrovascular events after transient ischemic attack: results from the CoRisk study. Stroke (2014) 45:2918–23. 10.1161/STROKEAHA.114.005584
    1. Minami S, Yamano S, Yamamoto Y, Sasaki R, Nakashima T, Takaoka M, et al. . Associations of plasma endothelin concentration with carotid atherosclerosis and asymptomatic cerebrovascular lesions in patients with essential hypertension. Hypertens Res. (2001) 24:663–70. 10.1291/hypres.24.663
    1. Ulm L, Hoffmann S, Nabavi DG, Hermans M, Mackert B-M, Hamilton F, et al. . The Randomized Controlled STRAWINSKI Trial: procalcitonin-guided antibiotic therapy after stroke. Front Neurol. (2017) 8:153. 10.3389/fneur.2017.00153
    1. Wang C, Gao L, Zhang Z-G, Li Y-Q, Yang Y-L, Chang T, et al. . Procalcitonin is a stronger predictor of long-term functional outcome and mortality than high-sensitivity C-reactive protein in patients with ischemic stroke. Mol Neurobiol. (2016) 53:1509–17. 10.1007/s12035-015-9112-7
    1. Li G, Zhu C, Li J, Wang X, Zhang Q, Zheng H, et al. . Increased level of procalcitonin is associated with total MRI burden of cerebral small vessel disease in patients with ischemic stroke. Neurosci Lett. (2018) 662:242–6. 10.1016/j.neulet.2017.10.040

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever